ID
16705
Description
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Deviation Log
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Keywords
Versions (1)
- 8/1/16 8/1/16 -
Uploaded on
August 1, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Deviation Log, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Deviation Log, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Description
Signature
Alias
- UMLS CUI-1
- C1519316
Description
Monitor Name
Data type
text
Alias
- UMLS CUI [1,1]
- C0027365
- UMLS CUI [1,2]
- C1521743
Description
Monitor Signature
Data type
text
Alias
- UMLS CUI [1,1]
- C1519316
- UMLS CUI [1,2]
- C1521743
Description
Signature Date
Data type
date
Alias
- UMLS CUI [1,1]
- C1519316
- UMLS CUI [1,2]
- C0011008
Similar models
Deviation Log, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C1704732 (UMLS CUI [1,2])
C2985654 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,2])
C1521743 (UMLS CUI [1,2])
C1521743 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])